Gilead leads in selling Atripla in new countries
US biotechnology firm Gilead Sciences says it will begin selling its HIV drug Atripla (efavirenz 600mg/ emtricitabine 200mg/ tenofovir disoproxil fumarate 300mg) in 12 countries located primarily in Latin America and the Asia-Pacific region.
Under the terms of the new agreement, Gilead will assume the lead role in the registration, manufacturing and distribution of Atripla in Argentina, Australia, Chile, Hong Kong, Israel, Mexico, New Zealand, Russia, Taiwan, Thailand, Turkey and Uruguay. Although partnered with US drug majors Merck & Co and Bristol-Myers Squibb, the firm will take the lead in making Atripla available in the 12 countries covered by this deal as soon as possible, and will share the revenues and costs associated with registration and distribution, noting that more countries may be added to this new accord by mutual consent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze